|
|
慢性肝病患者接种新型冠状病毒疫苗相关研究进展
|
Abstract:
新型冠状病毒肺炎(Coronavirus Disease 2019, COVID-19)由于其高传播率及人群普遍易感性成为威胁生命的全球健康负担。全国广泛推行新型冠状病毒疫苗接种以产生群体免疫。我国现存超3亿的慢性肝病患者，有研究表明，慢性肝病患者较健康人群对COVID-19有更高的易感性，且慢性肝病患者感染COVID-19后的重症率和死亡率升高，接种新冠疫苗可以有效降低新冠感染后的重症率和死亡率。目前有部分关于这一特殊人群接种新冠疫苗的安全性和有效性研究。本综述叙述了慢性肝病与COVID-19之间的关系，也叙述了新冠肺炎疫苗在慢性肝病这一特殊人群中的安全性和有效性。
Coronavirus Disease 2019 (COVID-19) has become a life-threatening global health burden due to its rapid transmission rate and general susceptibility. Vaccination against SARS-Cov-2 was actively promoted worldwide. There are more than 300 million patients with chronic liver diseases in China. Patients with chronic liver diseases have a higher susceptibility to COVID-19 than healthy people. They are considered to be at a high risk for severe COVID-19 and death. SARS-Cov-2 vaccination can reduce the disease severity and mortality effectively. There are some studies on the safety and effi-cacy of COVID-19 vaccination in patients with chronic liver diseases. This review focuses on the role of COVID-19 in chronic liver diseases and the safety and efficacy of COVID-19 vaccination in this spe-cial population.
| [1] | Whittaker, C., Walker, P., Alhaffar, M., et al. (2021) Under-Reporting of Deaths Limits Our Understanding of True Burden of COVID-19. BMJ, 375, Article No. n2239. https://doi.org/10.1136/bmj.n2239 |
| [2] | Biswas, M., Raham-an, S., Biswas, T.K., et al. (2020) Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology, 1-12. |
| [3] | Mukherjee, A., Kumar, G., Turuk, A., et al. (2023) Vaccination Saves Lives: A Real-Time Study of Patients with Chronic Diseases and Severe COVID-19 Infection. QJM: An International Journal of Medicine, 116, 47-56.
https://doi.org/10.1093/qjmed/hcac202 |
| [4] | Cicho？-Lach, H. and Michalak, A. (2021) Liver Injury in the Era of COVID-19. World Journal of Gastroenterology, 27, 377-390. https://doi.org/10.3748/wjg.v27.i5.377 |
| [5] | Alqahtani, S.A., Aljumah, A.A., Hashim, A., et al. (2020) Principles of Care for Patients with Liver Disease during the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation. Annals of Saudi Medicine, 40, 273-280. https://doi.org/10.5144/0256-4947.2020.273 |
| [6] | Boettler, T., Marjot, T., Newsome, P.N., et al. (2020) Impact of COVID-19 on the Care of Patients with Liver Disease: EASL-ESCMID Position Paper after 6 Months of the Pandemic. JHEP Reports, 2, Article ID: 100169.
https://doi.org/10.1016/j.jhepr.2020.100169 |
| [7] | Singh, S. and Khan, A. (2020) Clinical Characteristics and Out-comes of Coronavirus Disease 2019 among Patients with Preexisting Liver Disease in the United States: A Multicenter Research Network Study. Gastroenterology, 159, 768-771. https://doi.org/10.1053/j.gastro.2020.04.064 |
| [8] | Nagarajan, R., Krishnamoorthy, Y., Rajaa, S. and Hariharan, V.S. (2022) COVID-19 Severity and Mortality among Chronic Liver Disease Patients: A Systematic Review and Me-ta-Analysis. Preventing Chronic Disease, 19, E53.
https://doi.org/10.5888/pcd19.210228 |
| [9] | Steele, M.K., Couture, A., Reed, C., et al. (2022) Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented among Vaccinated Persons in the US, December 2020 to September 2021. JAMA Network Open, 5, e2220385. https://doi.org/10.1001/jamanetworkopen.2022.20385 |
| [10] | Tulimilli, S.V., Dallavalasa, S., Basavaraju, C.G., et al. (2022) Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vac-cines, 10, Article No. 1751.
https://doi.org/10.3390/vaccines10101751 |
| [11] | Ioannou, G.N., Liang, P.S., Locke, E., et al. (2021) Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventila-tion, and Mortality. Hepatology, 74, 322-335.
https://doi.org/10.1002/hep.31649 |
| [12] | Kim, D., Adeniji, N., Latt, N., et al. (2021) Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-Center Study. Clinical Gastroenterology and Hepatology, 19, 1469-1479.
https://doi.org/10.1016/j.cgh.2020.09.027 |
| [13] | Moon, A.M., Webb, G.J., Aloman, C., et al. (2020) High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-Existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry. Journal of Hepatology, 73, 705-708. https://doi.org/10.1016/j.jhep.2020.05.013 |
| [14] | Marjot, T., Moon, A.M., Cook, J.A., et al. (2021) Outcomes Fol-lowing SARS-CoV-2 Infection in Patients with Chronic Liver Disease: An International Registry Study. Journal of Hepatology, 74, 567-577.
https://doi.org/10.1016/j.jhep.2020.09.024 |
| [15] | Sagnelli, C., Montella, L., Grimaldi, P., et al. (2022) COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens, 11, Article No. 816. https://doi.org/10.3390/pathogens11070816 |
| [16] | Yu, Y., Li, X. and Wan, T. (2023) Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis. Digestive Diseases and Sciences, 68, 1615-1631. https://doi.org/10.1007/s10620-022-07687-2 |
| [17] | Marjot, T., Buescher, G., Sebode, M., et al. (2021) SARS-CoV-2 Infection in Patients with Autoimmune Hepatitis. Journal of Hepatology, 74, 1335-1343. https://doi.org/10.1016/j.jhep.2021.01.021 |
| [18] | Chavez-Tapia, N.C., Torre-Delgadillo, A., Tellez-Avila, F.I. and Uribe, M. (2007) The Molecular Basis of Susceptibility to Infection in Liver Cirrhosis. Current Medicinal Chemistry, 14, 2954-2958.
https://doi.org/10.2174/092986707782794041 |
| [19] | Sharma P., Kumar A., Anikhindi S., et al. (2021) Effect of COVID-19 on Pre-Existing Liver Disease: What Hepatologist Should Know? Journal of Clinical and Experimental Hepatology, 11, 484-493.
https://doi.org/10.1016/j.jceh.2020.12.006 |
| [20] | Premkumar, M. and Kedarisetty, C.K. (2021) Cytokine Storm of COVID-19 and Its Impact on Patients with and without Chronic Liver Disease. Journal of Clinical and Translational Hepatology, 9, 256-264.
https://doi.org/10.14218/JCTH.2021.00055 |
| [21] | Khandker, S.S., Godman, B., Jawad, M.I., et al. (2021) A Sys-tematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines, 9, Article No. 1387. https://doi.org/10.3390/vaccines9121387 |
| [22] | Amodio, E., Minutolo, G., Casuccio, A., et al. (2022) Adverse Reac-tions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System. Vaccines, 10, Article No. 345.
https://doi.org/10.3390/vaccines10030345 |
| [23] | Xia, S., Zhang, Y., Wang, Y., et al. (2021) Safety and Immuno-genicity of an Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Trial. The Lancet Infectious Diseases, 21, 39-51. https://doi.org/10.1016/S1473-3099(20)30831-8 |
| [24] | Novak, N., Tordesillas, L. and Cabanillas, B. (2022) Adverse Rare Events to Vaccines for COVID-19: From Hypersensitivity Reactions to Thrombosis and Thrombocytopenia. Inter-national Reviews of Immunology, 41, 438-447.
https://doi.org/10.1080/08830185.2021.1939696 |
| [25] | Chen, Y., Xu, Z., Wang, P., et al. (2022) New-Onset Auto-immune Phenomena Post-COVID-19 Vaccination. Immunology, 165, 386-401. https://doi.org/10.1111/imm.13443 |
| [26] | Wong, C.K.H., Mak, L.Y., Au, I., et al. (2022) Risk of Acute Liver Injury Following the mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccines. Journal of Hepatology, 77, 1339-1348.
https://doi.org/10.1016/j.jhep.2022.06.032 |
| [27] | Vojdani, A. and Kharrazian, D. (2020) Potential Antigenic Cross-Reactivity between SARS-CoV-2 and Human Tissue with a Possible Link to an Increase in Autoimmune Diseases. Clinical Immunology, 217, Article ID: 108480.
https://doi.org/10.1016/j.clim.2020.108480 |
| [28] | Roy, A., Verma, N., Singh, S., et al. (2022) Immune-Mediated Liver Injury Following COVID-19 Vaccination: A Systematic Review. Hepatology Communications, 6, 2513-2522. https://doi.org/10.1002/hep4.1979 |
| [29] | Cao, Z., Gui, H., Sheng, Z., Xin, H. and Xie, Q. (2022) Letter to the Editor: Exacerbation of Autoimmune Hepatitis after COVID-19 Vaccination. Hepatology, 75, 757-759. https://doi.org/10.1002/hep.32269 |
| [30] | Luo, D., Chen, X., Du, J., et al. (2023) Immunogenicity of COVID-19 Vaccines in Chronic Liver Disease Patients and Liver Transplant Recipients: A Systematic Review and Meta-Analysis. Liver International, 43, 34-48.
https://doi.org/10.1111/liv.15403 |
| [31] | Thuluvath, P.J., Robarts, P. and Chauhan, M. (2021) Analysis of Antibody Responses after COVID-19 Vaccination in Liver Transplant Recipients and Those with Chronic Liver Diseases. Journal of Hepatology, 75, 1434-1439.
https://doi.org/10.1016/j.jhep.2021.08.008 |
| [32] | Willuweit, K., Frey, A., Passenberg, M., et al. (2022) Patients with Liver Cirrhosis Show High Immunogenicity upon COVID-19 Vaccination but Develop Premature Deterioration of An-tibody Titers. Vaccines, 10, Article No. 377.
https://doi.org/10.3390/vaccines10030377 |
| [33] | Ruether, D.F., Schaub, G.M., Duengelhoef, P.M., et al. (2022) SARS-CoV2-Specific Humoral and T-Cell Immune Response after Second Vaccination in Liver Cirrhosis and Trans-plant Patients. Clinical Gastroenterology and Hepatology, 20, 162-172. https://doi.org/10.1016/j.cgh.2021.09.003 |
| [34] | Doi, H., Iyer, T.K., Carpenter, E., et al. (2012) Dysfunctional B-Cell Activation in Cirrhosis Resulting from Hepatitis C Infection Associated with Disappearance of CD27-Positive B-Cell Population. Hepatology, 55, 709-719.
https://doi.org/10.1002/hep.24689 |
| [35] | John, B.V., Sidney, B.A.T., Moon, A., et al. (2022) Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis. Clinical Gastro-enterology and Hepatology, 20, 2405-2408.
https://doi.org/10.1016/j.cgh.2022.05.038 |
| [36] | John, B.V., Deng, Y., Schwartz, K.B., et al. (2022) Postvaccination COVID-19 Infection Is Associated with Reduced Mortality in Patients with Cirrhosis. Hepatology, 76, 126-138. https://doi.org/10.1002/hep.32337 |
| [37] | Cao, Z., Zhang, C., Zhao, S., et al. (2022) COVID-19 Vaccines in Patients with Decompensated Cirrhosis: A Retrospective Cohort on Safety Data and Risk Factors Associated with Unvaccinated Status. Infectious Diseases of Poverty, 11, Article No. 56. https://doi.org/10.1186/s40249-022-00982-0 |
| [38] | Bakasis, A.-D., Bitzogli, K., Mouziouras, D., et al. (2022) Anti-body Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases. Viruses, 14, Article No. 207. https://doi.org/10.3390/v14020207 |
| [39] | Davidov, Y., Tsaraf, K., Cohen-Ezra, O., et al. (2022) Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine among Liver Transplantation Recipients. Liver Transplantation, 28, 215-223.
https://doi.org/10.1002/lt.26366 |
| [40] | D’Offizi. G., Agrati. C., Visco-Comandini. U., et al. (2022) Coordinated Cellular and Humoral Immune Responses after Two-Dose SARS-CoV2 mRNA Vaccination in Liver Transplant Recipi-ents. Liver International, 42, 180-186.
https://doi.org/10.1111/liv.15089 |
| [41] | Rabinowich, L., Grupper, A., Baruch, R., et al. (2021) Low Immunogenicity to SARS-CoV-2 Vaccination among Liver Transplant Recipients. Journal of Hepatology, 75, 435-438. https://doi.org/10.1016/j.jhep.2021.04.020 |
| [42] | Sakai, A., Morishita, T. and Matsunami, H. (2022) Antibody Re-sponse after a Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Liver Transplant Recipients. Transplant International, 35, Article ID: 10321.
https://doi.org/10.3389/ti.2022.10321 |
| [43] | Timmermann, L., Globke, B., Lurje, G., et al. (2021) Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients. Vaccines, 9, Article No. 1422. https://doi.org/10.3390/vaccines9121422 |
| [44] | Fix, O.K., Blumberg, E.A., Chang, K.M., et al. (2021) American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Dis-ease 2019 Infection in Patients with Liver Disease. Hepatology, 74, 1049-1064. https://doi.org/10.1002/hep.31751 |
| [45] | Kamar, N., Abravanel, F., Marion, O., et al. (2021) Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. New England Journal of Medicine, 385, 661-662. https://doi.org/10.1056/NEJMc2108861 |
| [46] | Oosting, S.F., van der Veldt, A., Fehrmann, R., et al. (2022) Immu-nogenicity after Second and Third mRNA-1273 Vaccination Doses in Patients Receiving Chemotherapy, Immunotherapy, or Both for Solid Tumours. The Lancet Oncology, 23, 833-835. https://doi.org/10.1016/S1470-2045(22)00203-0 |
| [47] | Peeters, M., Verbruggen, L., Teuwen, L., et al. (2021) Re-duced Humoral Immune Response after BNT162b2 Coronavirus Disease 2019 Messenger RNA Vaccination in Cancer Patients under Antineoplastic Treatment. ESMO Open, 6, Article ID: 100274. https://doi.org/10.1016/j.esmoop.2021.100274 |
| [48] | Levin, E.G., Lustig, Y., Cohen, C., et al. (2021) Waning Im-mune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. New England Journal of Medicine, 385, e84. https://doi.org/10.1056/NEJMoa2114583 |
| [49] | He, T., Zhou, Y., Xu, P., et al. (2022) Safety and Antibody Re-sponse to Inactivated COVID-19 Vaccine in Patients with Chronic Hepatitis B Virus Infection. Liver International, 42, 1287-1296. https://doi.org/10.1111/liv.15173 |
| [50] | Xiang, T., Liang, B., Wang, H., et al. (2021) Safety and Immu-nogenicity of a SARS-CoV-2 Inactivated Vaccine in Patients with Chronic Hepatitis B Virus Infection. Cellular & Mo-lecular Immunology, 18, 2679-2681.
https://doi.org/10.1038/s41423-021-00795-5 |
| [51] | Wang, J., Hou, Z., Liu, J., et al. (2021) Safety and Immunogen-icity of COVID-19 Vaccination in Patients with Non-Alcoholic Fatty Liver Disease (CHESS2101): A Multicenter Study. Journal of Hepatology, 75, 439-441.
https://doi.org/10.1016/j.jhep.2021.04.026 |
| [52] | Hegyi, P.J., Vancsa, S., Ocskay, K., et al. (2021) Metabolic Asso-ciated Fatty Liver Disease Is Associated with an Increased Risk of Severe COVID-19: A Systematic Review with Me-ta-Analysis. Frontiers in Medicine, 8, Article 626425.
https://doi.org/10.3389/fmed.2021.626425 |
| [53] | Pan, L., Huang, P., Xie, X., et al. (2021) Metabolic Associated Fatty Liver Disease Increases the Severity of COVID-19: A Meta-Analysis. Digestive and Liver Disease, 53, 153-157. https://doi.org/10.1016/j.dld.2020.09.007 |
| [54] | Singh, A., Hussain, S. and Antony, B. (2021) Non-Alcoholic Fatty Liver Disease and Clinical Outcomes in Patients with COVID-19: A Comprehensive Systematic Review and Me-ta-Analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15, 813-822. https://doi.org/10.1016/j.dsx.2021.03.019 |
| [55] | Duengelhoef, P., Hartl, J., Ruther, D., et al. (2022) SARS-CoV-2 Vaccination Response in Patients with Autoimmune Hepatitis and Autoimmune Cholestatic Liver Disease. United Euro-pean Gastroenterology Journal, 10, 319-329.
https://doi.org/10.1002/ueg2.12218 |
| [56] | Schneider, L., Schubert, L., Winkler, F., et al. (2022) SARS-CoV-2 Vac-cine Response in Patients with Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 20, 2145-2147. https://doi.org/10.1016/j.cgh.2022.04.006 |
| [57] | Li, H., Wang, Y., Ao, L., et al. (2022) Association between Immu-nosuppressants and Poor Antibody Responses to SARS-CoV-2 Vaccines in Patients with Autoimmune Liver Diseases. Frontiers in Immunology, 13, Article 988004.
https://doi.org/10.3389/fimmu.2022.988004 |
